

**PRESS RELEASE**

**Lipiodol®480 Injection 10mL approved  
for reimbursement in Japan  
when used for Transcatheter Arterial Chemo-embolization (TACE)**

**Villepinte, November 27, 2013**

Guerbet Japan announced that Lipiodol [LIPIODOL® 480 Injection 10 mL] (ethyl ester of iodinated fatty acids of poppy-seed oil injection, hereinafter referred to as “Lipiodol”) is approved for National Health Insurance reimbursement for Transcatheter Arterial Chemo-Embolization (TACE) <sup>(1)</sup> for hepatocarcinoma cellular when used with [Farmorubicin® for Injection 10 mg/50 mg] (non-proprietary name: epirubicin hydrochloride, hereinafter referred to as “Farmorubicin”, Pfizer Japan Inc.).

This approval for insurance reimbursement follows Ministry of Health, Labor and Welfare (MHLW) approval of a new Lipiodol indication for “adjustment of drugs and medical devices” received on September 13<sup>th</sup> 2013.

Steven Bleyl, Representative Director of Guerbet Japan commented “We are grateful as this approval came as a result of a strong collective effort by doctors associations, Ministry of Health Labour and Welfare together with Guerbet teams.”

It is estimated that there are 45,000 hepatocarcinoma cellular patients in Japan on a yearly basis, and TACE is performed for unresectable HCC which amounts to 30% of patients <sup>(2)</sup>.

1) Transcatheter arterial chemoembolization (TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Drugs are injected selectively into an artery directly supplying a tumor.

2) Jpn J Clin Oncol 2013;43(3)328–336, Liver vol. 48-3 117-140 (2007), Liver vol. 51-8 460-484 (2010)

**About Lipiodol**

*Discovered in 1901 by Marcel Guerbet, Lipiodol® is now commercialized widely in over 47 Countries, in Europe, Asia, Africa, Middle East, North and Latin America. The authorized indications for Lipiodol® may vary from country to country.*

**About Guerbet**

*A pioneer in the field of contrast agents with more than 80 years of experience, Guerbet is the only pharmaceutical group fully dedicated to medical imaging worldwide. As such it has a complete offering of contrast agents for X-ray, MRI and interventional radiology, along with a range of injectors and related medical devices to provide improved patient diagnosis and treatment.*

*To promote the discovery of new products and ensure its future growth, Guerbet devotes significant resources to research and development every year (approximately 10% of sales). Guerbet (GBT) is listed on NYSE Euronext Paris (Eurolist Compartment B – Mid Caps) and had sales of € 403 million in 2012 with a total workforce of 1,400 employees.*

*For additional information about Guerbet please go to [www.guerbet.co.jp](http://www.guerbet.co.jp) and [www.guerbet.com](http://www.guerbet.com)*

**Press Contacts:**

**Anne-Laure Delasalle, Communications Director**

Tel: + 33 (0)1 45 91 50 03

[anne-laure.delasalle@guerbet-group.com](mailto:anne-laure.delasalle@guerbet-group.com)

**Media Contact in Japan**

Steven Bleyl

Tel: +81 (0) 3.3288.5421

[steven.bleyl@guerbet-group.com](mailto:steven.bleyl@guerbet-group.com)

*This press release may contain forward-looking statements based on current assumptions and forecasts made by Guerbet Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performances of the company and the estimates given here. These factors include those discussed in Guerbet's public reports which are available on the Guerbet website at [www.guerbet.com](http://www.guerbet.com). The company assumes no liability whatsoever to update these forward-looking-statements or to conform them to future events or developments.*

*Lipiodol® is a trade mark registered by Guerbet*